The objective. A comparative study of the clinical efficacy and safety of using the antiviral drugs Triazavirine® and Tamiflu® in treatment of patients with influenza. Patients and methods. The study included a total of 127 patients aged 18 to 65 years with laboratory-confirmed diagnosis «moderate influenza infection». The absolute majority of patients (90.6%, n = 114) were diagnosed with type A influenza. The basic group comprised 82 patients who received Triazavirine® 1 capsule (250 mg) 3 times daily for 5 days. The control group consisted of 45 patients, receiving Tamiflu® 1 capsule (75 mg) 2 times daily for 5 days. The efficacy and safety of the antiviral drugs of study were assessed on the basis of clinical and laboratory data of examining patients in the dynamics of disease. Results. Among patients, receiving Triazavirine®, the time parameters to recovery and to disappearance of fever, headache and myalgia were less that among patients, receiving Tamiflu®. In patients, receiving Triazavirine®, the incidence of repeat detection of influenza virus RNA on the 5th day of treatment was lower than in patients of the control group. Patients of the basic group less frequently needed administration of symptomatic medications, and the duration of their use was less than among patients, who received Tamiflu®. Conclusion. The efficacy of Triazavirine® in therapy of patients with influenza exceeds that of Tamiflu® in a number of parameters. The use of Triazavirine® for treatment of patients with influenza is safe and well tolerated.